Daniel A Scott Selected Research

Conjugate Vaccines

1/2022	Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years.
12/2021	A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults ≥65 years of age with different prior pneumococcal vaccination.
10/2021	A phase 3, multicenter, single-arm, open-label study to assess the safety, tolerability, and immunogenicity of a single dose of 13-valent pneumococcal conjugate vaccine in Japanese participants aged 6-64 years who are considered to be at increased risk of pneumococcal disease and who are naive to pneumococcal vaccines.
10/2021	Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age.
10/2021	Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants in the United States.
3/2021	Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease After Introduction Into Routine Pediatric Use.
1/2021	A phase 4 study of the safety of the 13-valent pneumococcal conjugate vaccine in children 6 to 17 years of age in India.
1/2021	A randomized phase 1/2 study of the safety and immunogenicity of a multivalent pneumococcal conjugate vaccine in healthy adults 50 through 85 years of age.
1/2021	A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age.
4/2019	National impact of 13-valent pneumococcal conjugate vaccine on ambulatory care visits for otitis media in children under 5 years in the United States.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Daniel A Scott Research Topics

Disease

30	Pneumococcal Infections 01/2022 - 05/2010
11	Diphtheria 01/2022 - 06/2010
11	Tetanus 01/2022 - 06/2010
10	Whooping Cough (Pertussis) 01/2022 - 06/2010
7	Pneumonia (Pneumonitis) 01/2018 - 01/2015
4	Hepatitis B 01/2020 - 06/2010
3	Human Influenza (Influenza) 01/2020 - 04/2012
3	Infections 03/2015 - 02/2004
2	Pain (Aches) 01/2022 - 01/2021
2	Otitis Media 04/2019 - 01/2018
2	Pneumococcal Pneumonia 01/2018 - 03/2015
2	Fever (Fevers) 01/2017 - 08/2015
2	Guillain-Barre Syndrome 08/2015 - 02/2004
2	Poliomyelitis (Polio) 08/2011 - 06/2010
2	Diarrhea 01/2008 - 02/2007
1	Respiratory Syncytial Virus Infections 01/2022
1	Diabetes Mellitus 01/2020
1	Herpes Zoster 01/2020
1	Exanthema (Rash) 04/2019
1	Wounds and Injuries (Trauma) 04/2019
1	Injection Site Reaction 01/2018
1	Cellulitis 08/2015
1	Autoimmune Hemolytic Anemia (Cold Agglutinin Disease) 08/2015
1	Sickle Cell Anemia (Hemoglobin S Disease) 08/2015
1	Erythema 08/2015
1	Otitis 05/2015
1	Respiratory Tract Infections (Respiratory Tract Infection) 04/2015
1	Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) 06/2013
1	Chickenpox 04/2013
1	Measles 04/2013
1	Rubella (German Measles) 04/2013
1	Mumps 04/2013
1	Campylobacter Infections (Campylobacter Infection) 01/2008
1	Nausea 02/2007
1	Hyperemia 09/2004

Drug/Important Bio-Agent (IBA)

37	Conjugate VaccinesIBA 01/2022 - 05/2010
29	VaccinesIBA 01/2022 - 04/2010
8	Polysaccharides (Glycans)IBA 01/2021 - 04/2011
7	AntigensIBA 01/2017 - 12/2010
5	Pneumococcal Vaccines (Pneumococcal Polysaccharide Vaccine)IBA 10/2021 - 01/2015
4	Tetanus Toxoid (Vaccine, Tetanus)FDA Link 01/2022 - 08/2011
4	Pertussis VaccineIBA 01/2022 - 10/2015
4	23-valent pneumococcal capsular polysaccharide vaccineIBA 08/2015 - 08/2013
3	Diphtheria-Tetanus-acellular Pertussis Vaccines (Tripedia)FDA Link 04/2015 - 08/2011
3	AntibodiesIBA 04/2013 - 02/2004
3	Heptavalent Pneumococcal Conjugate Vaccine (Prevnar)IBA 08/2012 - 05/2010
2	Diphtheria Toxoid (Vaccine, Diphtheria)FDA Link 01/2022 - 08/2011
2	AntipyreticsIBA 01/2021 - 01/2017
2	Anti-Bacterial Agents (Antibiotics)IBA 04/2015 - 04/2010
2	Immunoglobulin G (IgG)IBA 12/2012 - 12/2010
2	diphtheria-tetanus-acellular pertussis-Hib-hepatitis B vaccineIBA 04/2012 - 06/2010
2	Pharmaceutical PreparationsIBA 09/2010 - 05/2010
2	GangliosidesIBA 01/2008 - 02/2004
1	Viral RNAIBA 01/2022
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 01/2022
1	13-valent pneumococcal vaccineIBA 01/2018
1	Hemagglutinins (Hemagglutinin)IBA 01/2017
1	Ibuprofen (Motrin)FDA LinkGeneric 01/2017
1	Acetaminophen (Paracetamol)FDA LinkGeneric 01/2017
1	Poliovirus VaccinesIBA 05/2013
1	Phosphates (Orthophosphate)IBA 04/2013
1	Proteins (Proteins, Gene)FDA Link 08/2012
1	CRM197 (non-toxic variant of diphtheria toxin)IBA 08/2012
1	serogroup C meningococcal conjugate vaccineIBA 01/2012
1	Immunoglobulin A (IgA)IBA 04/2010
1	Immunoglobulin M (IgM)IBA 01/2008
1	AutoantibodiesIBA 01/2008
1	Levofloxacin (Levaquin)FDA Link 02/2007
1	Azithromycin (Zithromax)FDA LinkGeneric 02/2007
1	AL-12182IBA 09/2004
1	EstersIBA 09/2004
1	ProdrugsIBA 09/2004
1	lipid-linked oligosaccharidesIBA 02/2004

Therapy/Procedure

1	Intramuscular Injections 01/2021
1	Ambulatory Care (Outpatient Care) 04/2019
1	Therapeutics 02/2007